Premium
Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes
Author(s) -
Shi Y.F.,
Pan C.Y.,
Hill J.,
Gao Y.
Publication year - 2005
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2005.01723.x
Subject(s) - orlistat , medicine , overweight , placebo , weight loss , diabetes mellitus , type 2 diabetes , gastroenterology , body mass index , obesity , endocrinology , alternative medicine , pathology
Aims Orlistat promotes weight loss in overweight and obese patients with Type 2 diabetes receiving hypoglycaemic treatment, but has not been investigated in patients with newly diagnosed and previously untreated Type 2 diabetes. We evaluated the efficacy of 24 weeks’ treatment with orlistat, combined with a mildly reduced‐calorie diet, on weight loss and glycaemic control in overweight and obese patients with newly diagnosed and previously untreated Type 2 diabetes. Methods A total of 249 Chinese patients (body mass index 25–40 kg/m 2 ) with recently diagnosed Type 2 diabetes were randomized to placebo ( n = 124) or orlistat 120 mg ( n = 125) three times daily; all patients followed a mildly reduced‐calorie diet. Patients had HbA 1c 6.5–8.5% (mean 7.3%) and had never received any glucose‐lowering medication. Results Orlistat‐treated patients achieved significantly greater weight loss at the study end than placebo‐treated patients (−5.4 vs. −2.4 kg; P < 0.0001). More orlistat than placebo patients lost ≥ 5% (60.5 vs. 26.8%; P < 0.0001) and ≥ 10% of their body weight (20.2 vs. 4.9%; P = 0.0002). A significantly greater decrease in HbA 1c from baseline was obtained with orlistat than placebo (−1.0 vs. −0.6%; P = 0.0008). Orlistat‐treated patients achieved a significantly greater decrease in fasting plasma glucose (−1.3 vs. −0.5 mmol/l; P = 0.0003) and in the 2‐h oral glucose tolerance test (−4.1 vs. −1.4 mmol/l; P < 0.0001) than placebo recipients. Also, more orlistat‐ than placebo‐treated patients improved from diabetic status to normal or impaired glucose tolerance (44.3 vs. 32.5%; P = 0.0763) after 24 weeks. Orlistat also produced improvements in lipid profiles and waist circumference. Conclusions In combination with a mildly reduced‐calorie diet, orlistat significantly reduces body weight, and improves glycaemic control and several cardiovascular risk factors in overweight and obese Chinese patients with newly diagnosed Type 2 diabetes.